ClinicalTrialsFinder
RecruitingNCT04104230

Quebec Pancreas Cancer Study

Sponsor

George Zogopoulos

Enrollment

2,000 participants

Start Date

Mar 12, 2012

Study Type

OBSERVATIONAL

Conditions

Pancreatic CancerPancreas CancerHereditary CancerBile Duct CancerDuodenal CancerGallbladder CancerFamilial Pancreatic CancerAmpullary CancerPancreas NeoplasmPancreas CystPancreatic Precancerous Condition

Summary

The Quebec Pancreas Cancer Study is a prospective clinic-based study consisting of clinical, family history and epidemiologic data, with accompanying biospecimens, from patients diagnosed with either pancreas cancer, a related cancer or a related pre-cancerous condition, and their families.

Eligibility

Min Age: 18 Years

Inclusion Criteria7

  • Individual diagnosed with pancreatic cancer.
  • Individual diagnosed with a related cancer (bile duct cancer, ampullary cancer, duodenal cancer, gallbladder cancer).
  • Individual diagnosed with pancreatic neoplasm or pancreatic cyst.
  • High-risk individuals with Familial Pancreatic Cancer (3 or more relatives affected with adenocarcinoma).
  • High-risk individuals with 2 first-degree relatives affected with young-onset pancreatic adenocarcinoma (≤ 50 years old).
  • High-risk individuals with one of the following Hereditary Cancer Syndromes: Peutz-Jeghers Syndrome (STK11 gene mutation), Familial Atypical Multiple Mole Melanoma Syndrome (CDKN2A gene mutation), or Hereditary Pancreatitis (PRSS1 gene mutation) with clinical manifestations.
  • High-risk individuals with one of the following Hereditary Cancer Syndromes: Hereditary Breast and Ovarian Cancer Syndrome (BRCA1, BRCA2 or PALB2 gene mutation), Lynch Syndrome (MLH1, MSH2, MSH6, PMS2 or EPCAM gene mutation), or Hereditary Breast Cancer (ATM gene mutation), WITH a family history of cancer.

Exclusion Criteria1

  • High-risk individuals with one of the following Hereditary Cancer Syndromes: Hereditary Breast and Ovarian Cancer Syndrome (BRCA1, BRCA2 or PALB2 gene mutation), Lynch Syndrome (MLH1, MSH2, MSH6, PMS2 or EPCAM gene mutation), or Hereditary Breast Cancer (ATM gene mutation), WITHOUT a family history of cancer.

Locations(1)

McGill University Health Centre

Montreal, Quebec, Canada

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04104230

Related Trials

A Pan-European Post-Authorisation Safety Study: Risk of Pancreatic Cancer Among Type 2 Diabetes Patients Who Initiated Exenatide as Compared With Those Who Initiated Other Non-Glucagon-Like Peptide 1 Receptor Agonists Based Glucose Lowering Drugs

NCT056635158 locations

A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies

NCT046786483 locations

A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors

NCT0624477126 locations

Autologous CAR-T Cells Targeting B7-H3 in PDAC

NCT061581391 location

ESPERANZA: External Control Arm Study for T-DXd for Patients With HER2 IHC3+ Solid Tumors

NCT0697316127 locations